Lucid Group has acquired the leading consulting firm, Synetic Life Sciences. The combined capabilities of Lucid and Synetic represents a unique value proposition for the industry, providing clients with an end-to-end partnership across the development and commercialisation journey, delivering transformative solutions across clients’ organisational needs and brand opportunities. It is a significant step forward for Lucid in its mission to improve global health outcomes by building an organisation designed for today’s healthcare challenges and capable of disrupting the service provider model.
Dennis O’Brien, Lucid Group CEO, commented, “Our goal has been to purposefully design an organisation with the capabilities to have a transformational impact for clients’ organisations, for their medicines and for the patients who will ultimately benefit from them. We have been searching for a consultancy with the right capability, ambition and culture to help make this a reality. I believe we have created an entirely new proposition, an end-to-end partnership which can disrupt the standard agency model, challenge traditional thinking and bring something genuinely exciting to our clients.”
Synetic is a management consulting firm dedicated to the life sciences industry. Its focus is on supporting clients globally with the design and implementation of operating models including building effective strategies, processes, capabilities and organisational constructs, as well as supporting robust planning and execution across the asset lifecycle. Synetic’s deep sector expertise enables bespoke solution development that supports clients in building fit for purpose operating models for commercial success.
Founded in 2007, Lucid Group is a strategic healthcare consultancy committed to having a meaningful impact on health outcomes. Lucid Group’s pioneering approaches to healthcare strategies and communication have received industry- wide recognition and have consistently led to market-leading growth. In recent years, Lucid Group has evolved its offering through the successful integration of a digital and creative consultancy and a US-based strategic brand consultant. These evolved capabilities now see Lucid partnering with commercial and medical teams across the commercialisation journey of a medicine from early asset strategy through to launch and beyond.
Matthew McLoughlin, Synetic founder and CEO commented, “We are excited about our future with Lucid and our ability to achieve so much more together. This combination will enable us to support clients all the way from strategy through design of operating models to seamless implementation at the portfolio and asset level. In addition to the successful track record and growth of Lucid, what also stood out for us was that we share a very similar mission and vision for our businesses.”
This is Lucid Group’s second acquisition backed by its investment partner Intermediate Capital Group (ICG) – a leading global alternative asset manager. ICG will continue to support Lucid Group’s ambitious team to acquire and build new capabilities that will add value to its clients, expand its international footprint, evolve its people development offering and achieve improved health outcomes.
Lucid Group was advised by Osborne Clarke (Legal), Proskauer Rose (Legal), Grant Thornton (Financial Due Diligence) and PWC (Tax).
For more information please contact:
Clare Reynolds, Commercial Integration and Business Development Director
Email: [email protected]